Sionna Therapeutics, Inc. (SION)
| Market Cap | 265.40M -76.2% |
| Revenue (ttm) | n/a |
| Net Income | -97.38M |
| EPS | -2.17 |
| Shares Out | 45.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 784,698 |
| Open | 5.97 |
| Previous Close | 6.06 |
| Day's Range | 5.82 - 6.06 |
| 52-Week Range | 4.01 - 54.97 |
| Beta | n/a |
| Analysts | Hold |
| Price Target | 15.17 (+158.43%) |
| Earnings Date | Aug 6, 2026 |
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for SION stock is "Hold." The 12-month stock price target is $15.17, which is an increase of 158.43% from the latest price.
News
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
SAN DIEGO, Aug. 19, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and direc...
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
SAN DIEGO--(BUSINESS WIRE)---- $SION #Health--Shareholder rights law firm Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and ...
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $SION--SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law.
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics
Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potentia...
Sionna Therapeutics rises 15.9%
Sionna Therapeutics (SION) is up 15.9%, or 71c to $5.21.
Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates
SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating potential violations of the federal securities laws involving Sionna Therapeu...
Sionna Therapeutics price target lowered to $5 from $38 at Freedom Broker
Freedom Broker analyst Ilya Zubkov lowered the firm’s price target on Sionna Therapeutics (SION) to $5 from $38 and keeps a Hold rating on the shares, telling investors that the…
Sionna Therapeutics rises 14.0%
Sionna Therapeutics (SION) is up 14.0%, or 63c to $5.13.
Sionna Therapeutics downgraded to Hold from Buy at JonesResearch
JonesResearch downgraded Sionna Therapeutics (SION) to Hold from Buy after SION-719 failed to show meaningful sweat chloride reduction in the Phase 2a PreciSION-CF trial. Following today’s update, the...
Sionna Therapeutics downgraded to Neutral from Buy at BTIG
BTIG downgraded Sionna Therapeutics (SION) to Neutral from Buy with no price target after the PreciSION CF trial did not meet its key activity endpoint. With SION-719 discontinued, the NBD1…
Sionna Therapeutics downgraded to Market Perform from Outperform at LifeSci Capital
LifeSci Capital downgraded Sionna Therapeutics (SION) to Market Perform from Outperform with a $6 price target
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
As previously reported, Guggenheim downgraded Sionna Therapeutics (SION) to Neutral from Buy and removed the firm’s prior price target after a study of Sionna’s NBD1 stabilizer combined with Vertex Ph...
Sionna Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Yatin Suneja downgraded Sionna Therapeutics (SION) to Neutral from Buy.
Citizens downgrades Sionna Therapeutics as SION-719 miss questions NBD1 thesis
As previously reported, Citizens downgraded Sionna Therapeutics (SION) to Market Perform from Outperform after SION-719 missed in the Phase 2a PreciSION CF study. Management is discontinuing SION-719 ...
Sionna Therapeutics falls -92.0%
Sionna Therapeutics (SION) is down -92.0%, or -$46.94 to $4.10.
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $672 from $605 and keeps a Buy rating on the shares after competitor Sionna Therapeutics (SION) reported that its…
Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low
The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.
Sionna Therapeutics downgraded to Market Perform from Outperform at Citizens
Citizens downgraded Sionna Therapeutics (SION) to Market Perform from Outperform.
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
Shares of American biotech company Vertex Pharmaceuticals ($VRTX) jumped about 7% on Monday after its top rival Sionna Therapeutics ($SION) reported the failure of a trial of its new cystic…
Sionna Therapeutics downgraded to Market Perform from Strong Buy at Raymond James
Raymond James analyst Christopher Raymond downgraded Sionna Therapeutics (SION) to Market Perform from Strong Buy without a price target Sion’s PreciSION CF Phase 2a trial was a clear failure, with…
Sionna Therapeutics upgraded to Sector Perform at RBC after 90% pullback
As previously reported, RBC Capital analyst Brian Abrahams upgraded Sionna Therapeutics (SION) to Sector Perform from Underperform with a price target of $5, down from $23. The firm’s thesis on…
Sionna Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital analyst Brian Abrahams upgraded Sionna Therapeutics (SION) to Sector Perform from Underperform.
Wedbush downgrades Sionna Therapeutics to Neutral following trial setback
As previously reported, Wedbush downgraded Sionna Therapeutics (SION) to Neutral from Outperform with a price target of $5, down from $53. The firm notes the company’s Phase 2a PreciSION study…
Sionna Therapeutics downgraded to Neutral from Outperform at Wedbush
Wedbush downgraded Sionna Therapeutics (SION) to Neutral from Outperform with a $5 price target
Sionna Therapeutics falls -91.8%
Sionna Therapeutics (SION) is down -91.8%, or -$46.85 to $4.18.